Delving into the Latest Updates on Talacotuzumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

IL-13 MAb-CSL, TAL

+ [7]

Target

CD123

Mechanism

CD123 inhibitors(Interleukin-3 receptor subunit alpha inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Natural killer cells stimulants(Natural killer cells stimulants)

Therapeutic Areas

NeoplasmsHemic and Lymphatic DiseasesImmune System Diseases+ [1]

Active Indication

Acute Myeloid LeukemiaSystemic Lupus Erythematosus

Inactive Indication

CD123 Positive Acute Myeloid LeukemiaMyelodysplastic Syndromes

Originator Organization

CSL Ltd.

Active Organization

CSL Ltd.

Janssen Global Services LLC

Inactive Organization

Janssen Research & Development LLC

Janssen Biotech, Inc.

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 146656H

Source: *****

Sequence Code 146663L

Source: *****

The purpose of this study is to assess the safety and tolerability of JNJ-56022473 following multiple subcutaneous (SC) study agent administrations in subjects with Systemic Lupus Erythematosus (SLE) and to determine whether premedication with corticosteroids is required to improve the tolerability of SC JNJ-56022473.

Start Date30 Jun 2017

Sponsor / Collaborator

Janssen Research & Development LLC

EUCTR2016-000327-10-FR / Not yet recruitingPhase 2

SINGLE AGENT JNJ-56022473 IN MDS AND AML PATIENTS FAILING HYPOMETHYLATING AGENT BASED THERAPY - SAMBA-trial

Start Date08 Jun 2017

Sponsor / Collaborator-

NCT03011034 / CompletedPhase 2

A Phase 2 Proof-of-Concept Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

The main purpose of the study is to evaluate the efficacy (transfusion independence [TI]) of talacotuzumab (JNJ-56022473) or daratumumab in transfusion-dependent participants with low or intermediate-1 risk Myelodysplastic Syndrome (MDS) whose disease has relapsed during treatment with or is refractory to Erythropoiesis-Stimulating Agent (ESAs).

Start Date14 Feb 2017

Sponsor / Collaborator

Janssen Research & Development LLC

100 Clinical Results associated with Talacotuzumab

Login to view more data

100 Translational Medicine associated with Talacotuzumab

Login to view more data

100 Patents (Medical) associated with Talacotuzumab

Login to view more data

144

Literatures (Medical) associated with Talacotuzumab

01 Nov 2024·Chemistry & Biodiversity

Contact Toxicity and Repellent Effects of Essential Oils from Toddalia asiatica Against Two Stored‐Product Insects

Article

Author: Wang, Jia‐Zhu ; Wang, Dan ; Zhang, Yu‐Chen ; Liu, Ao ; Qi, Yuan‐Tong ; Du, Shu‐Shan

AbstractInsect infestations continually endanger stored goods, underscoring the significance of discovering eco‐friendly insecticides for pest management. Essential oils (EOs) from different parts of Toddalia asiatica (leaf, fruit and branch) were extracted by hydrodistillation and analyzed by GC‐MS. Carvene, p‐cymene and muurolene are the principal compounds of T. asiatica leaf (TAL), T. asiatica fruit (TAF) and T. asiatica branch (TAB) EO respectively. Our work aimed to assess the contact toxicity and repellent effects of EOs on two storage pests, Tribolium castaneum and Lasioderma serricorne. All tested EOs exhibited obvious contact toxicity, especially, TAL EO against T. castaneum (33.48 μg/adult) and TAF EO against L. serricorne (16.42 μg/adult). Repellency tests revealed that TAL and TAF EOs, at a concentration of 78.63 nL/cm2, achieved nearing 100 % efficiency against T. castaneum. These results suggest that EOs of T. asiatica could be used as effective botanical insecticides for managing stored‐product insects.

01 Dec 2023·Biomedicine & Pharmacotherapy

Regulation of phosphosignaling pathways involved in transcription of cell cycle target genes by TRH receptor activation in GH1 cells

Article

Author: Novotny, Jiri ; Drastichova, Zdenka ; Trubacova, Radka

Thyrotropin-releasing hormone (TRH) is known to activate several cellular signaling pathway, but the activation of the TRH receptor (TRH-R) has not been reported to regulate gene transcription. The aim of this study was to identify phosphosignaling pathways and phosphoprotein complexes associated with gene transcription in GH1 pituitary cells treated with TRH or its analog, taltirelin (TAL), using label-free bottom-up mass spectrometry-based proteomics. Our detailed analysis provided insight into the mechanism through which TRH-R activation may regulate the transcription of genes related to the cell cycle and proliferation. It involves control of the signaling pathways for β-catenin/Tcf, Notch/RBPJ, p53/p21/Rbl2/E2F, Myc, and YY1/Rb1/E2F through phosphorylation and dephosphorylation of their key components. In many instances, the phosphorylation patterns of differentially phosphorylated phosphoproteins in TRH- or TAL-treated cells were identical or displayed a similar trend in phosphorylation. However, some phosphoproteins, especially components of the Wnt/β-catenin/Tcf and YY1/Rb1/E2F pathways, exhibited different phosphorylation patterns in TRH- and TAL-treated cells. This supports the notion that TRH and TAL may act, at least in part, as biased agonists. Additionally, the deficiency of β-arrestin2 resulted in a reduced number of alterations in phosphorylation, highlighting the critical role of β-arrestin2 in the signal transduction from TRH-R in the plasma membrane to transcription factors in the nucleus.

01 Jul 2023·iScience

CSL362 potently and specifically depletes pDCs in vitro and ablates SLE-immune complex-induced IFN responses

Article

Author: Wilson, Nicholas ; Jordan, Jarrat ; Linggi, Bryan ; Tai, Tsin Yee ; Oon, Shereen ; Hoi, Alberta ; Monaghan, Katherine A ; Ng, Milica ; Benson, Jacqueline ; Gamell, Cristina ; Morand, Eric ; Cesaroni, Matteo ; Sato, Takahiro ; Wicks, Ian

Systemic lupus erythematosus (SLE) is an autoimmune disease with significant morbidity and mortality. Type I interferon (IFN) drives SLE pathology and plasmacytoid dendritic cells (pDCs) are potent producers of IFN; however, the specific effects of pDC depletion have not been demonstrated. We show CD123 was highly expressed on pDCs and the anti-CD123 antibody CSL362 potently depleted pDCs in vitro. CSL362 pre-treatment abrogated the induction of IFNα and IFN-induced gene transcription following stimulation with SLE patient-derived serum or immune complexes. RNA transcripts induced in pDCs by ex vivo stimulation with TLR ligands were reflected in gene expression profiles of SLE blood, and correlated with disease severity. TLR ligand-induced protein production by SLE patient peripheral mononuclear cells was abrogated by CSL362 pre-treatment including proteins over expressed in SLE patient serum. These findings implicate pDCs as key drivers in the cellular activation and production of soluble factors seen in SLE.

100 Deals associated with Talacotuzumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14796

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Myeloid Leukemia	Preclinical	US	Janssen Biotech, Inc.	-
Acute Myeloid Leukemia	Preclinical	TR	Janssen Biotech, Inc.	-
Acute Myeloid Leukemia	Preclinical	IL	Janssen Biotech, Inc.	-
Acute Myeloid Leukemia	Preclinical	GB	Janssen Biotech, Inc.	-
Acute Myeloid Leukemia	Preclinical	TW	Janssen Biotech, Inc.	-
Acute Myeloid Leukemia	Discovery	IL	Janssen Biotech, Inc.	-
Acute Myeloid Leukemia	Discovery	TW	Janssen Biotech, Inc.	-
Acute Myeloid Leukemia	Discovery	US	Janssen Biotech, Inc.	-
Acute Myeloid Leukemia	Discovery	GB	Janssen Biotech, Inc.	-
Acute Myeloid Leukemia	Discovery	TR	Janssen Biotech, Inc.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03011034 (CTgov)	Phase 2	Myelodysplastic Syndromes	34	Talacotuzumab (Talacotuzumab)	zflfykqbyh(smwfiytmtw) = apflgxxcbe czqhmbjcbv (zjmidnnxxi, dzxdygitvr - zxeernhghf) View more	-	13 Mar 2020
				Daratumumab (Daratumumab)	zflfykqbyh(smwfiytmtw) = qifnvsgfib czqhmbjcbv (zjmidnnxxi, xlpczzaqjq - qdwlqqulcp) View more
NCT02472145 (CTgov)	Phase 2/3	Acute Myeloid Leukemia	326	Decitabine (Part B: Decitabine (Alone))	gucjshlbfe(iocwxnziik) = lotijjdobm qtfpbyikwu (prgfdbapvh, pipibonnmd - azsxzdhhmr) View more	-	28 Feb 2019
				Decitabine+JNJ-56022473 (Part B: Decitabine + JNJ-56022473)	gucjshlbfe(iocwxnziik) = zvspndhznk qtfpbyikwu (prgfdbapvh, brdbdmbhnk - vnndydyhum) View more